Skip to content
10-Q

Quarterly Report

Sarepta Therapeutics, Inc. SRPT

0001193125-26-208893

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 105.58M sh
Shares Diluted Q1 2026 · Mar 31, 2026 121.92M sh
Shares Diluted Q1 2026 · Mar 31, 2025 97.36M sh
Capex Q1 2026 · Mar 31, 2026 $2.08M
Capex Q1 2026 · Mar 31, 2025 $43.65M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$202.68M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$583.44M
Short Term Investments Q1 2026 · Mar 31, 2026 $188.74M
Short Term Investments Q1 2026 · Dec 31, 2025 $138.37M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $464.45M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $801.28M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $240.87M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.51B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.14B
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.14B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.53B
Current Liabilities Q1 2026 · Mar 31, 2026 $499.16M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.1B
Total Liabilities Q1 2026 · Mar 31, 2026 $1.67B
Total Liabilities Q1 2026 · Dec 31, 2025 $2.21B
Current Assets Q1 2026 · Mar 31, 2026 $2.31B
Current Assets Q1 2026 · Dec 31, 2025 $2.54B
Total Assets Q1 2026 · Mar 31, 2026 $3.18B
Total Assets Q1 2026 · Dec 31, 2025 $3.35B
Eps Diluted Q1 2026 · Mar 31, 2026 $2.88
Eps Diluted Q1 2026 · Mar 31, 2025 −$4.60
Eps Basic Q1 2026 · Mar 31, 2026 $3.15
Eps Basic Q1 2026 · Mar 31, 2025 −$4.60
Sga Expense Q1 2026 · Mar 31, 2026 $108.95M
Sga Expense Q1 2026 · Mar 31, 2025 $133.63M
Net Income Q1 2026 · Mar 31, 2026 $330.96M
Net Income Q1 2026 · Mar 31, 2025 −$447.51M
Operating Income Q1 2026 · Mar 31, 2026 $358.43M
Operating Income Q1 2026 · Mar 31, 2025 −$300.39M
Revenue Q1 2026 · Mar 31, 2026 $330.52M
Revenue Q1 2026 · Mar 31, 2025 $611.52M